A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

Published:2020-02 Issue:2 Volume:15 Page:190-202
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gascón Pere,Nagarkar Rajnish,Šmakal Martin,Syrigos Konstantinos N.,Barrios Carlos H.,Sánchez Jesús Cárdenas,Zhang Li,Henry David H.,Gordon David,Hirsh Vera,Kubota Kaoru,Orlov Sergey,Thomas Gary,Steinmetz Tilman,Kang Jin-Hyoung,Tomita Dianne K.,Fleishman Alexander N.,Park Joseph K.,De Oliveira Brandao Cisio

Funder

Amgen

AbbVie

Astellas Pharma

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Daiichi Sankyo

Exelixis

GlaxoSmithKline

ImClone

Lilly

Merck

Novartis

Pfizer

Roche

Genentech

Sanofi

Taiho Pharmaceutical

Pharmacyclics

Micah Robinson, PhD of Amgen

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Chemotherapy-induced anemia in adults: incidence and treatment;Groopman;J Natl Cancer Inst,1999

2. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study;Ludwig;Eur J Cancer,2009

3. Erythropoietins: a common mechanism of action;Elliott;Exp Hematol,2008

4. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin;Egrie;Exp Hematol,2003

5. Aranesp (darbepoetin alfa). Full Prescribing Information, Amgen Inc., Thousand Oaks, CA, 2019.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis;Clinical and Experimental Medicine;2024-07-05

2. Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials;Current Oncology;2023-08-24

3. Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy;Meditsinskiy sovet = Medical Council;2022-10-06

4. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2022-06-20

5. Patient blood management in oncology in the Russian Federation: Resolution to improve oncology care;Journal of Cancer Policy;2022-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3